Carglumic acid

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Research and development, NDA, Food, Research, Carglumic acid, Administration, Patient, Physician, PKU, Nitisinone, Phenylketonuria, Growth, Pharmaceutical industry

DEER PARK, Ill., May 09, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2024.

Key Points: 
  • •  Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth
    •  Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400
    DEER PARK, Ill., May 09, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2024.
  • We also launched Nitisinone and submitted an NDA for our highly anticipated ET-400 product candidate,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
  • Eton reported first quarter 2024 product sales of $8.0 million, representing 50% growth over the prior year, driven primarily by the ongoing momentum of ALKINDI SPRINKLE® and Carglumic Acid.
  • As previously announced, Eton Pharmaceuticals will host a its first quarter 2024 conference call as follows:

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
木曜日, 3月 14, 2024
Administration, Growth, Nitisinone, Patent, Patient, NDA, Orange Book, Trial of the century, Diurnal, Carglumic acid, Research and development, FDA, Endocrinology, Physician, Pharmaceutical industry

Eton reported fourth quarter 2023 product sales and royalty revenue of $7.3 million, representing a 109% year-over-year increase and 4% growth over the third quarter of 2023, driven primarily by the ongoing momentum of ALKINDI SPRINKLE and Carglumic Acid.

Key Points: 
  • Eton reported fourth quarter 2023 product sales and royalty revenue of $7.3 million, representing a 109% year-over-year increase and 4% growth over the third quarter of 2023, driven primarily by the ongoing momentum of ALKINDI SPRINKLE and Carglumic Acid.
  • Eton generated $0.4 million of operating cash during the fourth quarter of 2023, with total cash and cash equivalents of $21.4 million as of December 31, 2023.
  • Total net revenues were $7.3 million for the fourth quarter of 2023, compared to $8.5 million for the fourth quarter of 2022.
  • As previously announced, Eton Pharmaceuticals will host its fourth quarter 2023 conference call as follows:

Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results

Retrieved on: 
木曜日, 11月 9, 2023
NDA, Betaine, Carglumic acid, Nitisinone, Administration, Patient, Research, FDA, Marketing, Hand, R, Research and development, Growth, Hydrocortisone, Pharmaceutical industry, Video game

Product sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty revenue growth

Key Points: 
  • Product sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty revenue growth
    Generated $0.9 million in positive cash flow from operations; ended quarter with $22.1 million of cash on hand
    DEER PARK, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2023.
  • Eton reported third quarter 2023 product sales and royalty revenue of $7.0 million, representing 118% growth over the prior year period and 8% growth over the second quarter of 2023.
  • Product sales and royalty revenue for the third quarter of 2023 were up 8% over the second quarter of 2023.
  • As previously announced, Eton will host its third quarter 2023 conference call as follows:

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone

Retrieved on: 
水曜日, 10月 4, 2023
Insurance, Cornea, Keratitis, US Foods, Tyrosine, Diet, Medicine, Tell, Face, Chapter 11, Title 11, United States Code, Erythroderma, Skin, Light, DSM-IV codes, Inflammation, Carglumic acid, Mouth ulcer, Rash, Phenylalanine, Intellectual disability, Eton, Plasma, Vitamin, Hair, Photophobia, Allergy, Patient, Leukopenia, Blood, Itch, Immune system, Cover My Eyes (Pain and Heaven), Ageing, Rare, FDA, Conjunctivitis, Nosebleed, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Thrombocytopenia, Tongue, Food, Breast milk, Pharmaceutical industry, Nursing, Dietary supplement, Medical imaging, Birth control, Nitisinone

DEER PARK, Ill., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced it has entered into an agreement to acquire an abbreviated new drug application for Nitisinone Capsules via Oakrum Pharma, LLC’s Chapter 11 bankruptcy proceeding. The transaction has been approved by the bankruptcy court and is expected to be effective on October 12, 2023. The acquired product was approved by the U.S. Food and Drug Administration (FDA) in May of 2023 for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. It is estimated that less than 500 patients in the United States suffer from this ultra-rare condition.

Key Points: 
  • Nitisinone is our fourth FDA-approved product, and further advances us toward our goal of having ten commercial rare disease products on the market by the end of 2025.
  • Eton expects to launch the product in the first quarter of 2024 and plans to offer its Eton Cares support program to all patients.
  • Nitisinone is a prescription medicine used to treat adults and children with a hereditary disease called tyrosinemia type 1 (HT-1).
  • To report a suspected adverse event related to Nitisinone, contact Eton Pharmaceuticals, Inc. at: 1-855-224-0233 or the US Food and Drug Administration at www.fda.gov/medwatch or call 1-800-FDA-1088.

Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results

Retrieved on: 
木曜日, 8月 10, 2023
Lamotrigine, Betaine, NDA, Hydrocortisone, Trimethylglycine, Carglumic acid, Sale, Eton, Acquisition, Patient, Administration, Growth, Research and development, R, Rare, Research, FDA, Pharmaceutical industry, Video game

DEER PARK, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2023.

Key Points: 
  • DEER PARK, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2023.
  • Eton reported second quarter 2023 product sales and royalty revenue of $6.5 million, representing 175% growth over the prior year period and 22% growth over the first quarter of 2023.
  • Net Revenue: Net sales for the second quarter of 2023 were $12.0 million compared with $7.4 million in the prior year period.
  • As previously announced, Eton will host its second quarter 2023 conference call as follows:

SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

Retrieved on: 
月曜日, 7月 17, 2023
LSS, Pressure, Software as a service, SWK, Pregnancy, First Horizon Bank, Partnership, STI, Polypharmacy, Marketing, Share repurchase, BIOL, LeMaitre Vascular, Risk management, Medicine, Carglumic acid, Sale, Homocystinuria, Pulmonary hypertension, Patient, ROP, Decompression, GPO, Rare, FDA, AGS, Lumbar spinal stenosis, Security (finance), Life insurance, Pharmaceutical industry, Medical device, Management, Nursing, Cofix, Algorithm, Growth

We view repurchasing shares at the current discount to book as a highly accretive use of capital that benefits shareholders."

Key Points: 
  • We view repurchasing shares at the current discount to book as a highly accretive use of capital that benefits shareholders."
  • SWK has received $1.5mm of proceeds from the sale and anticipates receiving approximately $0.5 million in additional proceeds from the estate.
  • SWK will provide an update on the Flowonix finance receivable in our second quarter earnings release.
  • Signed a partnership with LeMaitre Vascular to distribute Aziyo's cardiovascular repair portfolio within the U.S., increasing sales representative coverage five-fold.

Eton Pharmaceuticals Reports First Quarter 2023 Financial Results

Retrieved on: 
木曜日, 5月 11, 2023
Endocrinology, Betaine, Carglumic acid, Eton, Adrenal insufficiency, Patient, Administration, Growth, Research and development, R, Rare, Research, Disease, Pharmaceutical industry, Video game, G&A

DEER PARK, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • DEER PARK, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2023.
  • Eton reported first quarter 2023 product sales and royalty revenue of $5.3 million, representing 144% growth over the prior year period and 52% growth over the fourth quarter of 2022.
  • The first quarter results benefited from key account conversions that the company believes are a direct result of its expanded sales team.
  • As previously announced, Eton Pharmaceuticals will host its first quarter 2023 conference call as follows:

Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results

Retrieved on: 
木曜日, 3月 16, 2023
Acquisition, Methanol, Eton, Adrenal insufficiency, Trimethylglycine, Poisoning, Exercise, Regulation of tobacco by the U.S. Food and Drug Administration, Carglumic acid, Research and development, Administration, Homocystinuria, Endocrinology, Patient, Hyperammonemia, Rare, Research, FDA, Growth, Marketing, Orphan drug, Food, IQVIA, NDA, R, Pharmaceutical industry, Video game, Betaine

DEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2022.

Key Points: 
  • DEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2022.
  • Eton reported fourth quarter 2022 product sales and royalty revenue of $3.5 million, representing 220% growth over the prior year and 9% growth over the third quarter of 2022.
  • The Company expects the sequential growth rate to increase in the first quarter of 2023 compared to the fourth quarter of 2022.
  • As previously announced, Eton Pharmaceuticals will host a its fourth quarter 2022 conference call as follows:

Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

Retrieved on: 
水曜日, 11月 2, 2022
Degenerative disease, Carglumic acid, GLOBE, Nasdaq, Company, FDA, Pharmaceutical industry

DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022.

Key Points: 
  • DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022.
  • Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m.
  • In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors.
  • Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.

Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference

Retrieved on: 
火曜日, 10月 18, 2022
Eton, Company, Webcast, Investor, Tablet, Carglumic acid, Degenerative disease, Pharmaceutical industry

The webcast will be accessible via the Companys website at https://ir.etonpharma.com/ in the Investors section under Events and Presentations.

Key Points: 
  • The webcast will be accessible via the Companys website at https://ir.etonpharma.com/ in the Investors section under Events and Presentations.
  • Eton will be participating in 1x1 meetings, which can be requested through your LD Micro representative.
  • Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases.
  • The Company currently commercializes ALKINDI SPRINKLE and Carglumic Acid tablets and has four additional rare disease products under development, including dehydrated alcohol injection and the ZENEO hydrocortisone autoinjector.